Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036127 · ClinicalTrials.gov registry record · Phase 2
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00036127: Completed Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT00036127 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036127, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00036127 record still lists
NCT00036127 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00036127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036127 about?
NCT00036127 is a clinical study titled "Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders". Study to learn if the alternate formulation is effective in agitated schizophrenic patients
What is the current status of trial NCT00036127?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036127?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00036127?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia